Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Biochemical Pharmacology|May 13, 2019
Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell lineNele Van Der Steen, Alessandro Leonetti, Kaylee Keller, et al.
Clinical Medicine Insights. Oncology|September 16, 2021
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective StudySebastiano Buti, Fabiana Perrone, Teresa Zielli, et al.
Molecular Biology Reports|April 15, 2021
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenariosLuigi Ventura, Letizia Gnetti, Maurizio Rossi, et al.
BMJ Supportive & Palliative Care|September 4, 2023
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictorsAlessandro Leonetti, Marianna Peroni, Virginia Agnetti, et al.
Targeted Oncology|October 19, 2023
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle RegulatorsFrancesco Volta, Silvia La Monica, Alessandro Leonetti, et al.
Clinical Lung Cancer|August 28, 2024
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLCAlessandro Leonetti, Veronica Cervati, Roberta Minari, et al.
Immunotherapy|September 16, 2020
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapyMelissa Bersanelli, Teresa Zielli, Fabiana Perrone, et al.
Cancers|May 14, 2025
SARS-CoV-2 Infection Risk and COVID-19 Prevalence and Mortality in Cancer Patients During the First Wave of COVID-19 Pandemic in a Virus Epicenter in Northern ItalyMatilde Corianò, Luca Isella, Chiara Tommasi, et al.
Cancers|November 13, 2021
Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the LiteratureMichela Verzè, Roberta Minari, Letizia Gnetti, et al.
Tumori|May 18, 2021
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitorsRoberta Minari, Francesco Bonatti, Giulia Mazzaschi, et al.
Pageof 7